JP2019094345A5 - - Google Patents

Download PDF

Info

Publication number
JP2019094345A5
JP2019094345A5 JP2019023478A JP2019023478A JP2019094345A5 JP 2019094345 A5 JP2019094345 A5 JP 2019094345A5 JP 2019023478 A JP2019023478 A JP 2019023478A JP 2019023478 A JP2019023478 A JP 2019023478A JP 2019094345 A5 JP2019094345 A5 JP 2019094345A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
compound
independently
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019023478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019094345A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019094345A publication Critical patent/JP2019094345A/ja
Publication of JP2019094345A5 publication Critical patent/JP2019094345A5/ja
Pending legal-status Critical Current

Links

JP2019023478A 2015-06-03 2019-02-13 心臓血管障害の治療にて用いるための4−ヒドロキシ−3−(ヘテロアリール)ピリジン−2−オン apjアゴニスト Pending JP2019094345A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562170215P 2015-06-03 2015-06-03
US62/170,215 2015-06-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017562603A Division JP6483288B2 (ja) 2015-06-03 2016-06-02 心臓血管障害の治療にて用いるための4−ヒドロキシ−3−(ヘテロアリール)ピリジン−2−オン apjアゴニスト

Publications (2)

Publication Number Publication Date
JP2019094345A JP2019094345A (ja) 2019-06-20
JP2019094345A5 true JP2019094345A5 (enExample) 2019-10-10

Family

ID=56131647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017562603A Active JP6483288B2 (ja) 2015-06-03 2016-06-02 心臓血管障害の治療にて用いるための4−ヒドロキシ−3−(ヘテロアリール)ピリジン−2−オン apjアゴニスト
JP2019023478A Pending JP2019094345A (ja) 2015-06-03 2019-02-13 心臓血管障害の治療にて用いるための4−ヒドロキシ−3−(ヘテロアリール)ピリジン−2−オン apjアゴニスト

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017562603A Active JP6483288B2 (ja) 2015-06-03 2016-06-02 心臓血管障害の治療にて用いるための4−ヒドロキシ−3−(ヘテロアリール)ピリジン−2−オン apjアゴニスト

Country Status (36)

Country Link
US (3) US10011594B2 (enExample)
EP (2) EP3530660A1 (enExample)
JP (2) JP6483288B2 (enExample)
KR (1) KR102066336B1 (enExample)
CN (1) CN107922401B (enExample)
AR (1) AR104884A1 (enExample)
AU (1) AU2016270903B2 (enExample)
CA (1) CA2988147C (enExample)
CL (1) CL2017003055A1 (enExample)
CO (1) CO2017013229A2 (enExample)
CY (1) CY1121938T1 (enExample)
DK (1) DK3303330T3 (enExample)
EA (1) EA034912B1 (enExample)
ES (1) ES2739526T3 (enExample)
HK (1) HK1247915B (enExample)
HR (1) HRP20191327T1 (enExample)
HU (1) HUE045546T2 (enExample)
IL (1) IL255951B (enExample)
LT (1) LT3303330T (enExample)
MA (1) MA41562B1 (enExample)
ME (1) ME03474B (enExample)
MX (1) MX378998B (enExample)
MY (1) MY189453A (enExample)
NZ (1) NZ738563A (enExample)
PE (1) PE20180506A1 (enExample)
PH (1) PH12017502158B1 (enExample)
PL (1) PL3303330T3 (enExample)
PT (1) PT3303330T (enExample)
RS (1) RS59220B1 (enExample)
SI (1) SI3303330T1 (enExample)
SM (1) SMT201900427T1 (enExample)
TN (1) TN2017000503A1 (enExample)
TW (1) TWI672299B (enExample)
UY (1) UY36705A (enExample)
WO (1) WO2016196771A1 (enExample)
ZA (1) ZA201708191B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985542C (en) 2015-05-20 2023-10-10 Amgen Inc. Triazole agonists of the apj receptor
RS59220B1 (sr) * 2015-06-03 2019-10-31 Bristol Myers Squibb Co 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primenu u lečenju kardiovaskularnih poremećaja
SG10201908839QA (en) 2015-10-14 2019-10-30 Bristol Myers Squibb Co 2,4-dihydroxy-nicotinamides as apj agonists
KR102678264B1 (ko) 2015-12-04 2024-06-24 브리스톨-마이어스 스큅 컴퍼니 아펠린 수용체 효능제 및 사용 방법
JP6948322B2 (ja) * 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン
JP6716711B2 (ja) 2016-03-24 2020-07-01 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Apjアゴニストとしての6−ヒドロキシ−4−オキソ−1,4−ジヒドロピリミジン−5−カルボキシアミド
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
KR102384668B1 (ko) 2016-06-14 2022-04-07 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온
EP3468952B1 (en) * 2016-06-14 2020-11-25 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
CN110072850B (zh) * 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
CN109704980B (zh) * 2019-02-16 2022-05-13 安徽大学 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法
CN109704981B (zh) * 2019-02-16 2022-01-28 安徽诺全药业有限公司 取代合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法
CN109734616B (zh) * 2019-02-16 2022-05-13 安徽诺全药业有限公司 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
CN120813365A (zh) 2023-01-03 2025-10-17 百爱及生物医药公司 爱帕琳肽受体激动剂和glp-1受体激动剂的组合疗法用于治疗与体重增加相关的疾病或病况
WO2025213190A1 (en) 2024-04-05 2025-10-09 BioAge Labs, Inc. Methods of treating a disease or condition associated with weight gain
WO2025251084A1 (en) 2024-05-31 2025-12-04 BioAge Labs, Inc. Methods of treating a disease or condition associated with weight gain

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001159A (en) 1910-07-25 1911-08-22 Elizabeth Nielsen Skirt-gage.
GB1472257A (en) 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US4866182A (en) 1988-02-18 1989-09-12 Merrell Dow Pharmaceuticals Inc. Cardiotonic alkanoyl and aroyl oxazolones
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
KR100838447B1 (ko) 2001-02-21 2008-06-16 아스트라제네카 아베 헤테로폴리시클릭 화합물 및 대사향성 글루타메이트수용체 길항제로서의 그의 용도
HRP20030751A2 (en) 2001-03-28 2005-08-31 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
WO2003020719A1 (en) 2001-09-03 2003-03-13 Takeda Chemical Industries, Ltd. 1,3-benzothiazinone derivatives and use thereof
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc N−アルキルスルフォニル置換アミド誘導体
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2005004818A2 (en) 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
US20060004001A1 (en) 2004-02-27 2006-01-05 Merz Pharma Gmbh & Co., Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP4777974B2 (ja) 2004-04-01 2011-09-21 イーライ リリー アンド カンパニー ヒスタミンh3受容体作用物質、製剤および治療的使用
NZ552187A (en) 2004-06-18 2010-08-27 Millennium Pharm Inc Thiophene-2-carboxamide derivatives
JP4982367B2 (ja) 2004-07-26 2012-07-25 イーライ リリー アンド カンパニー ヒスタミンh3受容体薬剤としてのオキサゾール誘導体、製造及び治療的使用
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
JP2008540626A (ja) * 2005-05-19 2008-11-20 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007023242A1 (en) 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
EA018128B1 (ru) 2006-01-23 2013-05-30 Амген Инк. Модуляторы аурора киназы, способы их получения и их применение
JP2007314516A (ja) 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd 2以上の置換基を有するベンゼン化合物を含有する医薬
CN101522623B (zh) 2006-08-03 2013-06-12 塔夫茨大学信托人 无潮红烟酸类似物和其使用方法
WO2008019090A2 (en) 2006-08-04 2008-02-14 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine-1-phosphate receptor
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
AU2007329512A1 (en) 2006-12-01 2008-06-12 Novartis Ag Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
CA2682019C (en) 2007-03-28 2016-08-09 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
AU2008326309C1 (en) * 2007-11-21 2015-03-12 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
RU2010135524A (ru) 2008-01-25 2012-02-27 Торрент Фармасьютикалз Лтд. (In) Фармацевтические комбинации
CN102046179B (zh) 2008-04-09 2015-01-14 英菲尼提制药公司 脂肪酸酰胺水解酶抑制剂
CN102047061A (zh) 2008-05-30 2011-05-04 福斯特韦勒能源股份公司 通过氧化燃料燃烧发电的方法和系统
BRPI0914942A2 (pt) 2008-06-30 2015-08-11 Cylene Pharmaceuticals Inc Compostos de oxindol
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
CA2742528A1 (en) * 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Apj receptor compounds
KR20120068947A (ko) 2009-09-24 2012-06-27 에프. 호프만-라 로슈 아게 Crac 조절제로서의 인돌 유도체
CN102510864A (zh) 2009-09-24 2012-06-20 弗·哈夫曼-拉罗切有限公司 抗病毒杂环化合物
US8609663B2 (en) 2009-11-18 2013-12-17 University Of Massachusetts Compounds for modulating TLR2
JP2013515000A (ja) 2009-12-18 2013-05-02 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬のプロドラッグ
CN102241621A (zh) 2010-05-11 2011-11-16 江苏恒瑞医药股份有限公司 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用
CN102906074A (zh) 2010-05-24 2013-01-30 东亚荣养株式会社 稠合咪唑衍生物
WO2012040532A1 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
JPWO2012074022A1 (ja) 2010-12-01 2014-05-19 旭硝子株式会社 イリジウムカチオン錯体および発光組成物
US20140057953A1 (en) 2011-03-03 2014-02-27 Rolf Hartmann Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
US8691861B2 (en) 2011-04-13 2014-04-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
EP2794601B1 (en) 2011-12-23 2019-02-20 Basf Se Isothiazoline compounds for combating invertebrate pests
WO2013164769A1 (en) * 2012-05-02 2013-11-07 Lupin Limited Substituted pyridine compounds as crac modulators
WO2013167633A1 (en) 2012-05-09 2013-11-14 Basf Se Acrylamide compounds for combating invertebrate pests
CN107569483B (zh) 2012-06-08 2021-09-17 高等教育联邦系统-匹兹堡大学 选自苄星青霉素化合物等的化合物在制备用于治疗炎症疾病的药物中的用途
WO2014006045A1 (en) 2012-07-02 2014-01-09 Max-Delbrück-Centrum für Molekulare Medizin Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
DK2897939T3 (en) * 2012-09-21 2017-05-08 Sanofi Sa BENZOIMIDAZOLCARBOXYL ACID AMIDE DERIVATIVES FOR THE TREATMENT OF METABOLIC OR CARDIOVASCULAR DISEASES
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2015017305A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
JP6199197B2 (ja) 2014-02-07 2017-09-20 花王株式会社 ポリオキシアルキレンアルキルエーテルカルボン酸塩の製造方法
JP2017071553A (ja) 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
PE20170186A1 (es) 2014-03-20 2017-04-01 Bayer Pharma AG Nuevos compuestos
WO2015191630A1 (en) 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CA2985542C (en) 2015-05-20 2023-10-10 Amgen Inc. Triazole agonists of the apj receptor
RS59220B1 (sr) * 2015-06-03 2019-10-31 Bristol Myers Squibb Co 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primenu u lečenju kardiovaskularnih poremećaja
KR101711744B1 (ko) 2015-07-16 2017-03-02 경희대학교 산학협력단 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층
SG10201908839QA (en) 2015-10-14 2019-10-30 Bristol Myers Squibb Co 2,4-dihydroxy-nicotinamides as apj agonists
WO2017091513A1 (en) 2015-11-24 2017-06-01 Daiichi Sankyo Company, Limited Novel azole derivatives as apelin receptor agonist
KR102678264B1 (ko) 2015-12-04 2024-06-24 브리스톨-마이어스 스큅 컴퍼니 아펠린 수용체 효능제 및 사용 방법
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
JP6948322B2 (ja) 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン
JP6716711B2 (ja) 2016-03-24 2020-07-01 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Apjアゴニストとしての6−ヒドロキシ−4−オキソ−1,4−ジヒドロピリミジン−5−カルボキシアミド
KR102384668B1 (ko) 2016-06-14 2022-04-07 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온
EP3468952B1 (en) 2016-06-14 2020-11-25 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
CN110072850B (zh) 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂

Similar Documents

Publication Publication Date Title
JP2019094345A5 (enExample)
JP2019031560A5 (enExample)
JP2016518437A5 (enExample)
JP2019034943A5 (enExample)
JP2013510825A5 (enExample)
JP2019524883A5 (enExample)
JP2019518766A5 (enExample)
JP2011509309A5 (enExample)
JP2013502431A5 (enExample)
JPWO2023195529A5 (enExample)
JP2005501120A5 (enExample)
JP2020500182A5 (enExample)
JP2018538304A5 (enExample)
JP2016540742A5 (enExample)
JP2020507589A5 (enExample)
JP2014521688A5 (enExample)
JP2013545791A5 (enExample)
JP2011513305A5 (enExample)
JP2010527985A5 (enExample)
JP2016503797A5 (enExample)
MX2023014630A (es) Activadores de dimetoxifenilalquilamina de receptores de serotonina.
JP2019535723A5 (enExample)
JP2013542267A5 (enExample)
JP2017502092A5 (enExample)
JP2008546770A5 (enExample)